Overview

A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism

Status:
Completed
Trial end date:
2019-12-19
Target enrollment:
Participant gender:
Summary
This trial is being conducted to assess the efficacy and safety of recombinant Human Prourokinase in the acute pulmonary embolism.
Phase:
Phase 2
Details
Lead Sponsor:
Tasly Biopharmaceuticals Co., Ltd.
Tasly Pharmaceuticals, Inc.
Treatments:
Saruplase
Tissue Plasminogen Activator